Recently, Axiogenesis hosted an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held on June 13, 2016, in Boston, Massachusetts, the symposium explored the topic of establishing global standards for iPSC-derived cell products. Because the conversation is critical to a wide range of stem cell industry stakeholders, the symposium was well-attended by representatives from across the pharmaceutical, biotechnology, and chemical sectors. Attendees also viewed case studies of iPS cells in drug development decision-making and biomedical research.
To further support this dialog within the global marketplace, Axiogenesis is now hosting Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016.
Attend this event to learn how experts in the pharmaceutical industry and leading academic institutions are using Axiogenesis’ cells and assays in drug discovery, safety/toxicology screening, and bioengeneering, as well as to understand current approaches to establishing and defining standards for these cellular models.
Axiogenesis has successfully staged such user meetings since 2014, all of which represented an opportunity to get insights into iPSC applications, as well as a broad opportunity for networking. Click here to view past Axiogenesis workshops.
During the upcoming workshop in Cologne, you will see live demonstrations of human iPSC-derived cardiomyocytes and neurons in action on various applications.
These live demonstrations will include:
- Automated Patch Clamp
- Multi Electrode Array
- HTS Calcium / Voltage Sensitive Dyes
- High Content Analysis
Confirmed speaker for the event include:
- Hua Rong Lu – Janssen
- Stephan Bedut – Servier
- Denise Franz – University of Rostock
- Marc Rogers – Metrion
- Francesco Pasqualini – Wyss Translational Center Zürich
- Benjamin Bader – Neuroproof
- Stefan Mann – Cytocentrics / Victor Chang Cardiac Research Institute
Seats to the event are limited, so click here to register while they are still available:
Axiogenesis was founded in 2001 and has been providing first in class stem cell-derived cells since 2007. Axiogenesis’ current focus lies on the development and validation of functional assays using neuronal and cardiac cells. The flagship offering is the Cor.4U human cardiomyocyte product family including cardiac fibroblasts. In the neural field Axiogenesis has launched iPSC-derived neuronal sub-types including dopaminergic neurons (Dopa.4U), peripheral neurons (Peri.4U), CNS neurons (CNS.4U) and Astrocytes (Astro.4U). Axiogenesis also offers licensing of proprietary disease models, e.g. Hypertrophic Cardiomyopathy (HCM), and tissue models for compound screening, as well as value-added fee-for-service assays for in vitro toxicology, safety pharmacology and drug discovery.